**Strong recent IPO activity and a robust late-2026 pipeline are shaping trader views on additional listings before year-end.** U.S. markets have already priced 251 IPOs raising substantial proceeds through early October 2026, tracking toward one of the strongest years since 2021 despite some pullbacks in smaller deals. Key drivers include AI infrastructure and biotech interest, with recent pricings such as ADARx Pharmaceuticals and Accelevation reflecting selective but open windows amid elevated Treasury yields. Anthropic’s targeted November listing and a pipeline of filers like Nscale underscore momentum, while postponements like Oura highlight sensitivity to valuation and demand. Upcoming catalysts include potential mega-deals and post-midterm market conditions that could influence final-quarter issuance.